Navigation Links
KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Date:2/27/2008

Third Quarter Revenues Up 38.8%, Nine-Month Revenues Up 40.6% ETHEX Revenue Up 57.8% for Third Quarter, Up 65.2% for Nine Months Ther-Rx

Revenue Up 16.6% for Third Quarter, Up 15.2% for Nine Months

ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today reported preliminary financial results for the third quarter and first nine months of fiscal 2008 ended December 31, 2007. The results reflected continued acceleration of revenue and profits at both the Company's branded drug subsidiary Ther-Rx Corporation, and generic/non-branded drug subsidiary ETHEX Corporation.

Net revenue, net income and diluted earnings per share amounts for both the third quarter and interim year-to-date periods are preliminary and subject to possible adjustments based upon completion of our financial statements which are being restated to reflect the outcome of a previously disclosed investigation into the Company's stock option grant practices. As previously reported, the New York Stock Exchange has granted an extension for trading of the Company's shares through March 31, 2008 required under the Exchange's rules due to the Company's delayed filing of its fiscal 2007 Annual Report on Form 10-K with the Securities and Exchange Commission. The Company expects by this date to have resolved all outstanding issues needed to make this filing and to complete its fiscal 2007 filings and restatements of previously reported results for the fiscal years 1996-2006.

THIRD QUARTER RESULTS

Net revenues for the third quarter increased 38.8% to $163.7 million, compared to $117.9 million for the third quarter of fiscal 2007. Ther-Rx net revenue grew 16.6% to $56.3 million, while ETHEX net revenues rose 57.8% to $102.2 million. ETHEX net revenue growth was positively affected by important ANDA products including the 100 mg and 200 mg strengths of Metoprolol Succinate Extended Release Tablets (generic alternative to Toprol(R)
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
3. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
4. Lotus Pharmaceuticals Raises $5 Million in Private Placement
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...k, Governor Patrick, and Lieutenant Governor Murra... In a groundbreaking move for antihunger work, Con...r all of the state,s hospitals to take an active r..., "With 554,000 people in Massachusetts now food ...ce at UMass Memorial Health Care in Worcester, "we...
(Date:11/9/2009)...sia-FirstCall/ -- Mindray Medical,International Li...rer and,marketer of medical devices worldwide, ann...lts for the third quarter and nine months ended Se...s as of September 30, 2009, -- Third quarter 20...f, 3.1% over the third quarter of 2008. Firs...
(Date:11/9/2009)...al Trade Commission Involvement Need to be Address...-USNewswire/ -- Inclusion of a provision in the Af...llowing insurance agents to sell health policies o...but other issues remain to be addressed in the Sen...essional Insurance Agents (PIA). ,, The languag...
(Date:11/9/2009)... Anderson, trainer to Gwyneth Paltrow, Shakira, Co...ents at her LA studio this week that are open to t...tional Meal Plan and Delivery Service, Tracy will ...yle Menu. She will also be teaching a Master Clas...d muscle structure work. Both events are open to ...
(Date:11/9/2009)...dy finds, , , MONDAY, Nov. 9 (HealthDay...vix (clopidogrel) works about the same in women as...found. , "After this study, I can say we can be...s very important drug," said Dr. Jeffrey S. Berger...k University Langone Medical Center in New York Ci...
Breaking Medicine News(10 mins):Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 2Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 3Health News:Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3
...may soon be replaced by a pill according to Europe... research which showed the effectiveness of the Gr...ies have long been treated with allergy shots. ...lerance of the immune system for the allergy-causi...
... today introduced a controversial licensing scheme...e homeopathic products// will be permitted to desc... With the aim to bring homeopathic remedies into...f to confirm their claims will be legitimized by i...
...ows that the prevalence of hay fever and eczema in...llergic reactions have risen sharply.// In t...d in the journal Thorax, the scientists at the Uni...rgic reactions to food have increased. Mentioning ...
...y that in Asian children must be given Vitamin D s... to avert the reappearance of deficiency symptoms....eficiency between 1994 and 2005 and have published...ns, general ill health, and stunted growth. And it...
...e saw a decrease in traumatic head injuries among ... a new report released on Wednesday.// When t...d at hospital admissions for traumatic head injuri...er, although head-injury hospitalizations showed a...
...ows old, the functioning of his lungs weakens. Acc...ravate this process.// An 8-year study was con... that men who had higher levels of long-standing a... hostility is associated with poorer pulmonary fun...
Other Medicine News:Health News:Doctors worried about Homeopathic licensing 2Health News:Eczema And Hay Fever Decline In UK While Allergic Reactions On The Rise 2Health News:Asian Children Need More Vitamin D Supplements 2
(Date:11/9/2009)..., PRINCETON JUNCTION, N.J., Nov. 9 /PRNewswire/ ...nest medical devices, but recognizing today,s econ...of high quality aesthetic laser systems, introduce...evice priced at under $50,000. ,, The MOSAIC C...s fractional technology including scanning and sta...
(Date:11/9/2009)..., ANN ARBOR, Mich., Nov. 9 Tho... Clinical Xpert(TM) CareFocus, a leading clinical ...entify at-risk patients in real-time and respond i...total cost of treatment. ,, This upgrade is ava...onal cost. ,, CareFocus 2.0 contains several ...
(Date:11/9/2009)..., SUNNYVALE, Calif., Nov. 9 /PRNewswire-FirstCal...harmaceutical company focused on developing and co...the treatment of immune mediated diseases and canc...sident, Preclinical Development will provide an ov... Merriman Curhan Ford,s 6th Annual Investor Summit...
Breaking Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 1Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 2Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 3Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 4Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 5Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 6Palatin Technologies Inc Reports Fourth Quarter and Fiscal Year End 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13880 7Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 1Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 2Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 3Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 4Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 5Bluepoint Surgical Group Co Sponsoring Weight Loss Surgery 26amp 3B Healthy Living Expo in Washington DC Area 56351 1Bluepoint Surgical Group Co Sponsoring Weight Loss Surgery 26amp 3B Healthy Living Expo in Washington DC Area 56351 2Bluepoint Surgical Group Co Sponsoring Weight Loss Surgery 26amp 3B Healthy Living Expo in Washington DC Area 56351 3Bluepoint Surgical Group Co Sponsoring Weight Loss Surgery 26amp 3B Healthy Living Expo in Washington DC Area 56351 4
...from Phase 1 Clinical Trial of SNS-595 in Acute,Le...SOUTH SAN FRANCISCO, Calif., June 11, 2007,/PRNews...resented,positive data from clinical studies of tw... SNS-595 and SNS-032, at the 12th,Congress of the ...ustria. , Interim Results from Sunesis, Phase 1 St...
...June 11, 2007-ReGen is pleased to announce that,a ...olostrinin, its,nutraceutical product which the Co...y cognitive function, was presented today at the,2...Surfers,Paradise, Queensland, Australia by Dr Mari... conference, which is being attended by key opinio...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2
...fers a simple and reproducible technique for arthr...tting tip requires no pre-drilling and the anchor ...yester suture. The potential pitfalls of suture ma...liding (I.S.S.™) Eyelet design. The sutures ...
Mini-Revo Suture Anchor System
...fers a simple and reproducible technique for arthr...tting tip requires no pre-drilling and the anchor ...yester suture. The potential pitfalls of suture ma...liding (I.S.S.™) Eyelet design. The sutures ...
...viding complete protection from initial crossing t...es. , ,Proxis is fast and easy to use. It doe...devices for removal of embolic debris. ,Prox.... ,Deployment, capture and recovery are quic...
Medicine Products: